CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 167 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,185,695 | -39.3% | 588,143 | -25.1% | 1.37% | -38.5% |
| Q2 2023 | $26,660,158 | +7.4% | 785,740 | +13.9% | 2.23% | +28.8% |
| Q1 2023 | $24,814,542 | -0.4% | 689,676 | +23.4% | 1.73% | -20.7% |
| Q4 2022 | $24,904,557 | +41.4% | 558,774 | -10.8% | 2.18% | +42.9% |
| Q3 2022 | $17,607,317 | -18.8% | 626,372 | -22.1% | 1.53% | -1.0% |
| Q2 2022 | $21,691,692 | +0.1% | 804,588 | +26.4% | 1.54% | -7.4% |
| Q1 2022 | $21,677,589 | -5.3% | 636,453 | +7.4% | 1.66% | +13.9% |
| Q4 2021 | $22,893,350 | +925.8% | 592,478 | +293.7% | 1.46% | +194.8% |
| Q3 2020 | $2,231,826 | -75.9% | 150,494 | -78.9% | 0.50% | -60.9% |
| Q2 2020 | $9,265,074 | – | 712,698 | – | 1.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |